These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses. Wang CY; Peng WJ; Kuo BS; Ho YH; Wang MS; Yang YT; Chang PY; Shen YH; Hwang KP PLoS Pathog; 2023 Apr; 19(4):e1010870. PubMed ID: 37079651 [TBL] [Abstract][Full Text] [Related]
50. An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2. Zhang L; Narayanan KK; Cooper L; Chan KK; Devlin CA; Aguhob A; Shirley K; Rong L; Rehman J; Malik AB; Procko E bioRxiv; 2022 Mar; ():. PubMed ID: 35378764 [TBL] [Abstract][Full Text] [Related]
51. SARS-CoV-2 neutralizing camelid heavy-chain-only antibodies as powerful tools for diagnostic and therapeutic applications. Schlör A; Hirschberg S; Amor GB; Meister TL; Arora P; Pöhlmann S; Hoffmann M; Pfaender S; Eddin OK; Kamhieh-Milz J; Hanack K Front Immunol; 2022; 13():930975. PubMed ID: 36189209 [TBL] [Abstract][Full Text] [Related]
52. Identifying epitopes responsible for neutralizing antibody and DC-SIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus. Shih YP; Chen CY; Liu SJ; Chen KH; Lee YM; Chao YC; Chen YM J Virol; 2006 Nov; 80(21):10315-24. PubMed ID: 17041212 [TBL] [Abstract][Full Text] [Related]
53. Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay. D'Apice L; Trovato M; Gramigna G; Colavita F; Francalancia M; Matusali G; Meschi S; Lapa D; Bettini A; Mizzoni K; Aurisicchio L; Di Caro A; Castilletti C; De Berardinis P Front Immunol; 2022; 13():981693. PubMed ID: 36225911 [TBL] [Abstract][Full Text] [Related]
54. Omicron BA.1 Mutations in SARS-CoV-2 Spike Lead to Reduced T-Cell Response in Vaccinated and Convalescent Individuals. Emmelot ME; Vos M; Boer MC; Rots NY; de Wit J; van Els CACM; Kaaijk P Viruses; 2022 Jul; 14(7):. PubMed ID: 35891550 [TBL] [Abstract][Full Text] [Related]
55. A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode. Zhao D; Liu L; Liu X; Zhang J; Yin Y; Luan L; Jiang D; Yang X; Li L; Xiong H; Xing D; Zheng Q; Xia N; Tao Y; Li S; Huang H J Nanobiotechnology; 2022 Sep; 20(1):411. PubMed ID: 36109732 [TBL] [Abstract][Full Text] [Related]
56. Inhibition of SARS-CoV-2 wild-type (Wuhan-Hu-1) and Delta (B.1.617.2) strains by marine sulfated glycans. Dwivedi R; Sharma P; Farrag M; Kim SB; Fassero LA; Tandon R; Pomin VH Glycobiology; 2022 Sep; 32(10):849-854. PubMed ID: 35788318 [TBL] [Abstract][Full Text] [Related]
57. Risk evaluation and mitigation strategies for newly detected SARS-CoV-2 Omicron BF.7 subvariant: A brief report. Nazmunnahar ; Ahmed I; Islam MR Health Sci Rep; 2023 Mar; 6(3):e1127. PubMed ID: 36875932 [TBL] [Abstract][Full Text] [Related]
58. Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England. Strasser ZH; Greifer N; Hadavand A; Murphy SN; Estiri H JAMA Netw Open; 2022 Oct; 5(10):e2238354. PubMed ID: 36282501 [TBL] [Abstract][Full Text] [Related]
59. Nano-size dependent protein corona formation by SARS-CoV-2 Omicron spike protein over gold nano-colloid and reversible aggregation. Yokoyama K; Lam T; Santariello J; Ichiki A Colloids Surf A Physicochem Eng Asp; 2022 Aug; 647():128967. PubMed ID: 35466287 [TBL] [Abstract][Full Text] [Related]
60. SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022. Cheng SM; Mok CKP; Chan KC; Ng SS; Lam BH; Luk LL; Ko FW; Chen C; Yiu K; Li JK; Chan KK; Tsang LC; Poon LL; Hui DS; Peiris M Euro Surveill; 2022 May; 27(18):. PubMed ID: 35514306 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]